| 1 |
Dhariwal NK, Lynde GC. Update in the management of patients with preeclampsia[J]. Anesthesiol Clin, 2017, 35 (1): 95-106.
|
| 2 |
Phillips C, Boyd M. Assessment, management, and health implications of early-onset preeclampsia[J]. Nurs Womens Health, 2016, 20 (4): 400-414.
|
| 3 |
Cheng SB, Sharma S. Preeclampsia and health risks later in life: an immunological link[J]. Semin Immunopathol, 2016, 38 (6): 699-708.
|
| 4 |
Phipps E, Prasanna D, Brima W, et al. Preeclampsia: updates in pathogenesis, definitions, and guidelines[J]. Clin J Am Soc Nephrol, 2016, 11 (6): 1102-1113.
|
| 5 |
Varland IE, Vevatne K, Brinchmann BS. An integrative review of mothers' experiences of preeclampsia[J]. J Obstet Gynecol Neonatal Nurs, 2016, 45 (3): 300-307.
|
| 6 |
Morton A. Imitators of preeclampsia: a review[J]. Pregnancy Hypertens, 2016, 6 (1): 1-9.
|
| 7 |
Harmon AC, Cornelius DC, Amaral LM, et al. The role of inflammation in the pathology of preeclampsia[J]. Clin Sci (Lond), 2016, 130 (6): 409-419.
|
| 8 |
Rahimzadeh M, Norouzian M, Arabpour F, et al. Regulatory T-cells and preeclampsia: an overview of literature[J]. Expert Rev Clin Immunol, 2016, 12 (2): 209-227.
|
| 9 |
Das UN. Cytokines, angiogenic, and antiangiogenic factors and bioactive lipids in preeclampsia[J]. Nutrition, 2015, 31 (9): 1083-1095.
|
| 10 |
Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia [J]. Curr Opin Nephrol Hypertens, 2015, 24 (2): 131-138.
|
| 11 |
Lambert G, Brichant JF, Hartstein G, et al. Preeclampsia: an update[J]. Acta Anaesthesiol Belg, 2014, 65 (4): 137-149.
|
| 12 |
Birdir C, Janssen K, Stanescu AD, et al. Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia[J]. Arch Gynecol Obstet, 2015, 292 (5): 1033-1042.
|
| 13 |
Mihu D, Razvan C, Malutan A, et al. Evaluation of maternal systemic inflammatory response in preeclampsia[J]. Taiwan J Obstet Gynecol, 2015, 54 (2): 160-166.
|
| 14 |
Jelliffe-Pawlowski LL, Baer RJ, Currier RJ, et al. Early-onset severe preeclampsia by first trimester pregnancy-associated plasma protein A and total human chorionic gonadotropin[J]. Am J Perinatol, 2015, 32 (7): 703-712.
|
| 15 |
Chedraui P, Solis EJ, Bocci G, et al. Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia[J]. J Matern Fetal Neonatal Med, 2013, 26 (3): 226-232.
|
| 16 |
Bozkurt M, Yumru AE, Sahin L, et al. Troponin I and D-dimer levels in preeclampsia and eclampsia: prospective study[J]. Clin Exp Obstet Gynecol, 2015, 42 (1): 26-31.
|
| 17 |
Kwon JH, Kim YH, Kwon JY, et al. Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia[J]. J Perinat Med, 2011, 39 (5): 507-513.
|
| 18 |
Oujo B, Perez-Barriocanal F, Bernabeu C, et al. Membrane and soluble forms of endoglin in preeclampsia[J]. Curr Mol Med, 2013, 13 (8): 1345-1357.
|
| 19 |
Lai J, Pinas A, Syngelaki A, et al. Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia[J]. J Matern Fetal Neonatal Med, 2013, 26 (8): 733-737.
|
| 20 |
Boucoiran I, Thissier-Levy S, Wu Y, et al. Risks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies[J]. Am J Perinatol, 2013, 30 (7): 607-612.
|
| 21 |
El-Sherbiny W, Soliman A, El-Mazny A. Elevated serum-soluble Fas in preeclampsia: correlation with clinical, laboratory, and Doppler parameters[J]. Hypertens Pregnancy, 2011, 30 (2): 221-230.
|
| 22 |
Resic Karara J, Zekic Tomas S, Marusic J, et al. Fas and FasL expression in placentas complicated with intrauterine growth retardation with and without preeclampsia[J]. J Matern Fetal Neonatal Med, 2016, 29 (7): 1154-1159.
|
| 23 |
Christ-Crain M, Fenske W. Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis[J]. Nat Rev Endocrinol, 2016, 12 (3): 168-176.
|
| 24 |
Yilman M, Erenler AK, Baydin A. Copeptin: a diagnostic factor for critical patients[J]. Eur Rev Med Pharmacol Sci, 2015, 19 (16): 3030-3036.
|
| 25 |
Lukaszyk E, Malyszko J. Copeptin: pathophysiology and potential clinical impact[J]. Adv Med Sci, 2015, 60 (2): 335-341.
|
| 26 |
王林国，俞文华，董晓巧，等. 血浆和肽素浓度对重型颅脑损伤后急性创伤性凝血病的预测价值[J/CD]. 中华危重症医学杂志（电子版），2015，8(5):300-305.
|
| 27 |
田正丰，俞文华，董晓巧，等. 血浆和肽素浓度对急性创伤性进展性出血性脑损伤的预测价值[J/CD]. 中华危重症医学杂志（电子版），2016，9(3):169-173.
|